Raise: Research highlights pressures experienced by young people today
Two important education reports were launched this week at an event hosted by David Gonski AC. The 2024 Australian Youth Barometer: Understanding Young People in Australia Today and the Independent Evaluation of the Raise Mentoring Program highlight the multiple demands on young people’s mental health. The Raise report outlined some of the philanthropically supported programs having positive outcomes the space.
Drumroll please… Conference program released for Adelaide 2024!
Join hundreds of your colleagues and friends for three days of inspirational ideas and insights.
Hopes for a breakthrough in childhood diseases underpinned by 10-year funding relationship
An enduring relationship that has formed between the Stafford Fox Medical Research Foundation (SFMRF) and Murdoch Children's Research Institute (MCRI) over a decade has been attributed to enabling the latter to develop world-first research into stem cell medicine that could result in treatments for rare or currently incurable and devastating childhood diseases, including heart disease and brain cancer.
Australian Philanthropy Awards 2024 – in pictures
Take a look at some of the highlights and key moments from the Australian Philanthropy Awards Showcase event including guests, award recipients, finalists, presenters and more.
‘Stop talking ourselves down as a sector’
Practices, mindset and behaviours that are needed to evolve for the NFP and charity sector – as voted by its leaders.
Latest Telescope report highlights cost-of-living and collaboration as big issues for 2024
A new report has revealed the philanthropic sector’s issues and ideas for the coming year. Philanthropy Australia’s second annual Better Philanthropy Telescope report has taken the pulse of the sector to help identify the trends, issues and opportunities that will shape the giving agenda this year.
How impact investment is making a difference in global health equity
Impact investing is playing a critical and growing role in the development of medicines to treat ‘neglected diseases’ affecting the world’s poorest and most underserved peoples. These medicines would not otherwise be developed by the pharmaceutical industry, which is primarily driven by financial returns. Here, Mark Sullivan AO, founder and managing director of Medicines Development for Global Health, an Australian biopharmaceutical not-for-profit, describes how this finance model is supporting the development of Moxidectin – a potential gamechanger for the WHO’s roadmap to ending river blindness by 2030.




